盘龙药业
(002864)
| 流通市值：20.04亿 | | | 总市值：28.78亿 |
| 流通股本：7398.46万 | | | 总股本：1.06亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 716,922,919.85 | 455,356,633.75 | 210,115,513.5 | 980,828,104.35 |
| 营业收入 | 716,922,919.85 | 455,356,633.75 | 210,115,513.5 | 980,828,104.35 |
| 利息收入 | - | - | - | 0 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 621,571,912.66 | 391,905,428.8 | 179,227,823.4 | 846,854,849.06 |
| 营业成本 | 274,057,046.13 | 171,037,480.65 | 79,960,232.85 | 412,745,633.63 |
| 利息支出 | - | - | - | 0 |
| 手续费及佣金支出 | - | - | - | 0 |
| 退保金 | - | - | - | 0 |
| 赔付支出净额 | - | - | - | 0 |
| 提取保险合同准备金净额 | - | - | - | 0 |
| 保单红利支出 | - | - | - | 0 |
| 分保费用 | - | - | - | 0 |
| 税金及附加 | 8,354,269.09 | 5,569,712.94 | 2,493,118.7 | 10,896,473.55 |
| 销售费用 | 285,227,399.41 | 182,179,446.22 | 87,561,923.7 | 361,096,662.97 |
| 管理费用 | 48,012,252.21 | 31,294,733.1 | 12,693,130.72 | 57,694,187.12 |
| 研发费用 | 23,846,304.9 | 14,256,105.42 | 3,717,714.19 | 20,256,386.31 |
| 财务费用 | -17,925,359.08 | -12,432,049.53 | -7,198,296.76 | -15,834,494.52 |
| 其中:利息费用 | 2,639,361.19 | 1,710,512.26 | 802,101.4 | 6,111,134.73 |
| 其中:利息收入 | 20,617,912.28 | 14,187,267.19 | 8,010,392.93 | 22,064,468.01 |
| 加:投资收益 | -171,589.02 | -117,289.76 | -51,809.02 | -1,556,588.91 |
| 资产处置收益 | -4,470.58 | -128.18 | - | 168,160.88 |
| 资产减值损失(新) | -7,083.23 | -200,203.8 | -263,294.44 | -992,178.92 |
| 信用减值损失(新) | -3,870,745 | -5,339,050.16 | -2,084,277.04 | -3,900,792.15 |
| 其他收益 | 6,739,055.06 | 5,033,588.78 | 2,173,803.48 | 7,167,566.53 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 98,036,174.42 | 62,828,121.83 | 30,662,113.08 | 134,859,422.72 |
| 加:营业外收入 | 5,138,360.49 | 5,110,646.63 | 5,038,900.06 | 441,476.26 |
| 减:营业外支出 | 1,598,463.71 | 270,305.04 | 64,224.65 | 6,052,229.31 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 101,576,071.2 | 67,668,463.42 | 35,636,788.49 | 129,248,669.67 |
| 减:所得税费用 | 12,293,422.61 | 8,233,016.01 | 4,578,897.16 | 17,703,576.6 |
| 六、净利润 | 89,282,648.59 | 59,435,447.41 | 31,057,891.33 | 111,545,093.07 |
| 持续经营净利润 | 89,282,648.59 | 59,435,447.41 | 31,057,891.33 | 111,545,093.07 |
| 归属于母公司股东的净利润 | 89,571,690.67 | 59,653,263.68 | 31,147,203.65 | 110,432,177.41 |
| 少数股东损益 | -289,042.08 | -217,816.27 | -89,312.32 | 1,112,915.66 |
| (一)基本每股收益 | 0.85 | 0.57 | 0.3 | 1.15 |
| (二)稀释每股收益 | 0.85 | 0.57 | 0.3 | 1.13 |
| 九、综合收益总额 | 89,282,648.59 | 59,435,447.41 | 31,057,891.33 | 111,545,093.07 |
| 归属于母公司股东的综合收益总额 | 89,571,690.67 | 59,653,263.68 | 31,147,203.65 | 110,432,177.41 |
| 归属于少数股东的综合收益总额 | -289,042.08 | -217,816.27 | -89,312.32 | 1,112,915.66 |
| 公告日期 | 2024-10-28 | 2024-08-28 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |